Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

Talactoferrin fails to improve progression-free or overall survival in randomized trial vs. placebo
Tue, 08/07/2012 - 18:10
Author
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

I was disappointed to learn today that the FORTIS-M trial, a study of 720 patients with previously treated advanced NSCLC randomized to receive talactoferrin-alpha (TLF) or placebo, was reported as being negative in a press release late yesterday.   The primary endpoint was overall survival, and not only was the study quite negative for any improvement in survival (median 7.5 months with talactoferrin vs. 7.7 months on placebo arm), it also demonstrated no improvement in progression-free survival.

We haven't received any additional details, and perhaps there will be a subset identified for further study, but officials from the company indicated that they're likely to be shutting down research on it and cutting their losses.  The stock for Agennix, the manufacturers of TLF, dropped nearly 80% over the course of the last day, so this may well shut down the company.

Of course, I'm disappointed on several levels.  Not only was I truly very hopeful about this agent, partly because of its efficacy in phase II trials and partly because of its extremely favorable tolerability (it actually seems to reduce side effects when paired with chemo, compared with chemo alone).  Although I'd hope to see results of a trial of chemo + TLF vs. chemo + placebo, it seems that's unlikely to happen.

What went wrong?  The best answer is that I don't know, and I don't think anyone does.  It may be that this is just one of too many agents that looked very promising in early work, but once the larger trials more carefully tested it and held it up to higher scrutiny, it didn't live up to that promise.  I must admit that TLF got a fair test in the form of a 720 patient randomized trial that appears to not show any hint of benefit (as far as we know from a press release; the full data should be presented at a meeting in the next couple of months).  

I'm quite saddened that an agent I was pretty hopeful about fail to emerge as a new effective treatment for lung cancer, but there are others out there.

Next Previous link

Previous PostNext Post

Related Content

Image
Mandarin LCVL
Video
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit: https://www.youtube.com/playlist?list=PLWsyUmdjLXhGnSxobmz4CBP3pxAj7nDa…;  
Image
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
Article
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Image
Blood Cancer OncTalk
Video
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

JOIN THE CONVERSATION
Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
Concerned
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29